Dyadic International, Inc. Stock price

Equities

DYAI

US26745T1016

Biotechnology & Medical Research

Delayed Nasdaq 12:58:06 2024-03-28 pm EDT 5-day change 1st Jan Change
1.66 USD +1.84% Intraday chart for Dyadic International, Inc. +1.84% +3.11%
Sales 2023 * 3.05M Sales 2024 * 4.3M Capitalization 46.96M
Net income 2023 * -6M Net income 2024 * -8M EV / Sales 2023 * 15.4 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 10.9 x
P/E ratio 2023 *
-7.09 x
P/E ratio 2024 *
-6.39 x
Employees 7
Yield 2023 *
-
Yield 2024 *
-
Free-Float 48.87%
More Fundamentals * Assessed data
Dynamic Chart
Dyadic Says Patrick Lucy Named Board Chair; Joseph Hazelton Appointed COO MT
Dyadic International, Inc. Announces Management Changes CI
Dyadic International, Inc. announced that it has received $6 million in funding CI
Dyadic International, Rabian Collaborate to Develop Rabies Vaccine MT
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa CI
Transcript : Dyadic International, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells CI
More news
1 day+6.13%
1 week+6.13%
Current month+28.15%
1 month+22.70%
3 months+10.19%
6 months-7.98%
Current year+7.45%
More quotes
1 week
1.55
Extreme 1.55
1.73
1 month
1.31
Extreme 1.31
1.73
Current year
1.19
Extreme 1.19
1.73
1 year
1.19
Extreme 1.19
2.40
3 years
1.12
Extreme 1.12
6.89
5 years
1.12
Extreme 1.12
10.98
10 years
0.80
Extreme 0.8
10.98
More quotes
Managers TitleAgeSince
Founder 69 78-12-31
Director of Finance/CFO 48 16-05-31
Chief Tech/Sci/R&D Officer 66 14-05-05
Members of the board TitleAgeSince
Founder 69 78-12-31
Director/Board Member 80 15-04-30
Chairman 69 14-06-11
More insiders
Date Price Change Volume
24-03-28 1.66 +1.84% 21 132
24-03-27 1.63 +3.16% 7,612
24-03-26 1.58 -3.66% 12,137
24-03-25 1.64 +2.50% 28,144
24-03-22 1.6 -1.84% 5,876

Delayed Quote Nasdaq, March 28, 2024 at 10:19 am EDT

More quotes
Dyadic International, Inc. is a global biotechnology platform company with operations in the United States. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It has licensed this technology to third parties, such as Abengoa Bioenergy, BASF,Codexis and others, for industrial applications. This technology is based on the Thermothelomyces heterothallica fungus, namely C1. The C1-cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products, including enzymes and other proteins for human and animal health. The Company also developed the Dapibus thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of proteins, metabolites and other biologic products for use in non-pharmaceutical applications, such as food, nutrition and wellness.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.63 USD
Average target price
7.5 USD
Spread / Average Target
+360.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Dyadic International, Inc. - Nasdaq